BiotechTube

Sabril®

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infantile Spasms

Conditions

Infantile Spasms, Refractory Complex Partial Seizures in Adults

Trial Timeline

Aug 1, 2009 → —

NCT ID
NCT01073579

About Sabril®

Sabril® is a pre-clinical stage product being developed by Lundbeck for Infantile Spasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01073579. Target conditions include Infantile Spasms, Refractory Complex Partial Seizures in Adults.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01073579Pre-clinicalCompleted

Competing Products

16 competing products in Infantile Spasms

See all competitors
ProductCompanyStageHype Score
TSHA-101Taysha Gene TherapiesPhase 1/2
36
MAS825 + PlaceboNovartisPhase 2
52
alglucosidase alfa + alglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 2
51
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
84
RadiprodilUCBPhase 2
49
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
20
VigabatrinLundbeckApproved
82
NusinersenBiogenPre-clinical
20
GWP42003-PJazz PharmaceuticalsPhase 3
74
GWP42003-PJazz PharmaceuticalsPhase 3
74
Cerliponase AlfaBioMarin PharmaceuticalPre-clinical
20
Cholic AcidsMirum PharmaceuticalsPhase 3
74
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
74
ATB200 + AT2221Amicus TherapeuticsPre-clinical
20
RP-L401Rocket PharmaceuticalsPhase 1
25

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82